-$0.07 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) This Quarter
Wall Street brokerages expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce earnings of ($0.07) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.19). Ironwood Pharmaceuticals reported earnings per share of ($0.28) during the same quarter last year, which indicates a positive year-over-year growth rate of 75%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, August 5th.
According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to $0.06. For the next financial year, analysts expect that the business will report earnings of $0.56 per share, with EPS estimates ranging from $0.17 to $1.13. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.10). The business had revenue of $68.73 million for the quarter, compared to analysts’ expectations of $81.93 million. During the same quarter last year, the firm earned ($0.25) earnings per share. Ironwood Pharmaceuticals’s revenue was down .6% on a year-over-year basis.
In other news, CFO Gina Consylman sold 4,055 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $10.53, for a total value of $42,699.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $19,568,000. Northern Trust Corp grew its holdings in shares of Ironwood Pharmaceuticals by 2.0% in the fourth quarter. Northern Trust Corp now owns 1,712,129 shares of the biotechnology company’s stock worth $17,738,000 after purchasing an additional 33,007 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 1,658,754 shares of the biotechnology company’s stock worth $17,184,000 after purchasing an additional 94,453 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 425.5% in the fourth quarter. Millennium Management LLC now owns 1,373,080 shares of the biotechnology company’s stock worth $14,225,000 after purchasing an additional 1,111,814 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the second quarter worth approximately $13,487,000. 98.89% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:IRWD traded up $0.06 during trading on Tuesday, reaching $10.72. The stock had a trading volume of 967,381 shares, compared to its average volume of 1,204,881. The business’s fifty day moving average is $10.79. Ironwood Pharmaceuticals has a 52 week low of $9.07 and a 52 week high of $20.33. The stock has a market capitalization of $1.66 billion, a PE ratio of -11.28 and a beta of 1.68.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Further Reading: What are the advantages of the Stochastic Momentum Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.